Hepatotoxicity of Avacopan: Real-World Incidence and Confirmed Cases of Severe Drug-Induced Liver Injury in a US National Rheumatology Registry.
INTRODUCTION Avacopan, an oral C5a receptor inhibitor, approved for ANCA-associated vasculitis (AAV) in 2021. Following FDA reports of 76 worldwide drug induced liver injury (DILI) cases (66 in Japan, 5 in the US), the agency requested market withdrawal, which the manufacturer declined. US risk has not been quantified...